Marine Ingredients acquires softgel production facility
![](/46/pdcnewsitem/03/83/46/marine%20ingredients.jpg)
Employees currently working in Miami will transfer to Innova Softgel, a newly formed subsidiary of Marine Ingredients.
Aenova Group has signed a definitive agreement to sell Swiss Caps USA’s softgel manufacturing facility in Miami, FL, to Marine Ingredients, a leading omega-3 manufacturer. As part of the agreement, the employees currently working in Miami will transfer from Swiss Caps USA to Innova Softgel, LLC, a newly formed subsidiary of Marine Ingredients. Both parties agreed not to disclose financial details of the transaction, which is expected to be closed by the end of December.
"The Swiss Caps acquisition is very attractive to us for a number of reasons. First and foremost, is the talented Swiss Caps team of seasoned professionals who take pride in producing high quality products for a broad spectrum of US and international customers — servicing these customers will remain their focus. Additionally, Marine Ingredients will gain the last piece in our quest to be fully vertically-integrated, improving the traceability and transparency of the entire supply chain for customers. Finally, because of Swiss Caps' various certifications and licenses, including OTC, TGA, NSF, Halal and MSC, we will be better able to serve the market as global business opportunities are pursued,” said Olav Sandnes, President of Marine Ingredients.
“We are extremely pleased to find a strong organization such as Marine Ingredients to carry on the future success of the Miami site,” stated Marcus Boening, CFO, Aenova Group.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance